Acrivon Therapeutics (Acrivon Therapeutics) Price-to-Tangible-Book : 1.86 (As of May. 17, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Acrivon Therapeutics Price-to-Tangible-Book?

As of today (2024-05-17), Acrivon Therapeutics's share price is $8.89. Acrivon Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $4.77. Hence, Acrivon Therapeutics's Price to Tangible Book Ratio of today is 1.86.

The historical rank and industry rank for Acrivon Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

ACRV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91 Med: 1.52 Max: 1.92
Current: 1.79

During the past 4 years, Acrivon Therapeutics's highest Price to Tangible Book Ratio was 1.92. The lowest was 0.91. And the median was 1.52.

ACRV's Price-to-Tangible-Book is ranked better than
68.92% of 1226 companies
in the Biotechnology industry
Industry Median: 2.85 vs ACRV: 1.79

A closely related ratio is called PB Ratio. As of today, Acrivon Therapeutics's share price is $8.89. Acrivon Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $4.77. Hence, Acrivon Therapeutics's P/B Ratio of today is 1.86.

Acrivon Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Acrivon Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrivon Therapeutics Price-to-Tangible-Book Chart

Acrivon Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

1.48

0.91

Acrivon Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial								1.73	1.92	1.53	0.91	1.50

Competitive Comparison of Acrivon Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Acrivon Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrivon Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Acrivon Therapeutics's Price-to-Tangible-Book falls into.

Acrivon Therapeutics Price-to-Tangible-Book Calculation

Acrivon Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	8.89	/	4.77
	=	1.86

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Acrivon Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Acrivon Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrivon Therapeutics (Acrivon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472

Website

https://www.acrivon.com

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Executives

Mary Miller	officer: Chief Legal Officer	C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Peter Blume-jensen	director, officer: President and CEO	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Chione Ltd	10 percent owner	SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101, 6015, LARNACA G4 CY
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Rasmus Holm-jorgensen	officer: Chief Financial Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Eric Devroe	officer: Chief Operating Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Anastasis Nikolaou	10 percent owner	C/O CHIONE LTD/ SIMOU MENARDOU 5, KIFISIA COURT,OFFICE 225, LARNACA G4 6015
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Erick Gamelin	officer: Chief Medical Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Kristina Masson	director, officer: EVP - Business Operations	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116